MannKind expands United Therapeutics partnership for second inhaled therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
August 27, 2025 8:05 AM EDTInitial collaboration led to Tyvaso DPI®, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension
DANBURY, Conn. and BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Â MannKind Corporation (Nasdaq: MNKD) today announced that United Therapeutics Corporation (Nasdaq: UTHR) has exercised its optiongranted under the companies 2018 license and collaboration... More
